vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and S&T BANCORP INC (STBA). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $102.1M, roughly 1.9× S&T BANCORP INC). S&T BANCORP INC runs the higher net margin — 34.4% vs -14.6%, a 48.9% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 2.6%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

AXSM vs STBA — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.9× larger
AXSM
$196.0M
$102.1M
STBA
Higher net margin
STBA
STBA
48.9% more per $
STBA
34.4%
-14.6%
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
2.6%
STBA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AXSM
AXSM
STBA
STBA
Revenue
$196.0M
$102.1M
Net Profit
$-28.6M
$35.1M
Gross Margin
Operating Margin
-13.8%
Net Margin
-14.6%
34.4%
Revenue YoY
65.0%
Net Profit YoY
61.9%
5.0%
EPS (diluted)
$-0.55
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
STBA
STBA
Q1 26
$102.1M
Q4 25
$196.0M
$105.3M
Q3 25
$171.0M
$103.0M
Q2 25
$150.0M
$100.1M
Q1 25
$121.5M
$93.8M
Q4 24
$118.8M
$94.3M
Q3 24
$104.8M
$96.4M
Q2 24
$87.2M
$96.9M
Net Profit
AXSM
AXSM
STBA
STBA
Q1 26
$35.1M
Q4 25
$-28.6M
$34.0M
Q3 25
$-47.2M
$35.0M
Q2 25
$-48.0M
$31.9M
Q1 25
$-59.4M
$33.4M
Q4 24
$-74.9M
$33.1M
Q3 24
$-64.6M
$32.6M
Q2 24
$-79.3M
$34.4M
Operating Margin
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
-13.8%
40.3%
Q3 25
-27.0%
42.6%
Q2 25
-24.5%
40.0%
Q1 25
-46.9%
44.5%
Q4 24
-61.1%
43.8%
Q3 24
-59.8%
43.0%
Q2 24
-89.5%
44.2%
Net Margin
AXSM
AXSM
STBA
STBA
Q1 26
34.4%
Q4 25
-14.6%
32.3%
Q3 25
-27.6%
33.9%
Q2 25
-32.0%
31.9%
Q1 25
-48.9%
35.6%
Q4 24
-63.1%
35.1%
Q3 24
-61.7%
33.8%
Q2 24
-91.0%
35.5%
EPS (diluted)
AXSM
AXSM
STBA
STBA
Q1 26
$0.94
Q4 25
$-0.55
$0.88
Q3 25
$-0.94
$0.91
Q2 25
$-0.97
$0.83
Q1 25
$-1.22
$0.87
Q4 24
$-1.54
$0.86
Q3 24
$-1.34
$0.85
Q2 24
$-1.67
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
STBA
STBA
Cash + ST InvestmentsLiquidity on hand
$322.9M
Total DebtLower is stronger
$100.8M
Stockholders' EquityBook value
$88.3M
$1.4B
Total Assets
$689.8M
$9.9B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
$322.9M
$163.4M
Q3 25
$325.3M
$196.2M
Q2 25
$303.0M
$203.1M
Q1 25
$300.9M
$211.8M
Q4 24
$315.4M
$244.8M
Q3 24
$327.3M
$228.1M
Q2 24
$315.7M
$246.3M
Total Debt
AXSM
AXSM
STBA
STBA
Q1 26
$100.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
AXSM
AXSM
STBA
STBA
Q1 26
$1.4B
Q4 25
$88.3M
$1.5B
Q3 25
$73.7M
$1.5B
Q2 25
$73.1M
$1.4B
Q1 25
$53.2M
$1.4B
Q4 24
$57.0M
$1.4B
Q3 24
$92.9M
$1.4B
Q2 24
$102.9M
$1.3B
Total Assets
AXSM
AXSM
STBA
STBA
Q1 26
$9.9B
Q4 25
$689.8M
$9.9B
Q3 25
$669.3M
$9.8B
Q2 25
$639.8M
$9.8B
Q1 25
$596.7M
$9.7B
Q4 24
$568.5M
$9.7B
Q3 24
$561.5M
$9.6B
Q2 24
$548.2M
$9.6B
Debt / Equity
AXSM
AXSM
STBA
STBA
Q1 26
0.07×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
STBA
STBA
Operating Cash FlowLast quarter
$-18.7M
Free Cash FlowOCF − Capex
$-18.7M
FCF MarginFCF / Revenue
-9.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
$-18.7M
$133.6M
Q3 25
$1.0M
$40.5M
Q2 25
$-32.4M
$28.3M
Q1 25
$-43.4M
$28.7M
Q4 24
$-26.2M
$173.4M
Q3 24
$-18.6M
$27.6M
Q2 24
$-30.1M
$44.7M
Free Cash Flow
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
$-18.7M
$128.8M
Q3 25
$988.0K
$39.9M
Q2 25
$-32.4M
$27.1M
Q1 25
$-43.7M
$27.0M
Q4 24
$-26.2M
$170.4M
Q3 24
$-18.7M
$26.9M
Q2 24
$-30.2M
$43.9M
FCF Margin
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
-9.6%
122.4%
Q3 25
0.6%
38.7%
Q2 25
-21.6%
27.1%
Q1 25
-36.0%
28.8%
Q4 24
-22.1%
180.7%
Q3 24
-17.9%
28.0%
Q2 24
-34.6%
45.3%
Capex Intensity
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
0.0%
4.5%
Q3 25
0.0%
0.6%
Q2 25
0.0%
1.2%
Q1 25
0.3%
1.8%
Q4 24
0.0%
3.1%
Q3 24
0.1%
0.7%
Q2 24
0.1%
0.9%
Cash Conversion
AXSM
AXSM
STBA
STBA
Q1 26
Q4 25
3.93×
Q3 25
1.16×
Q2 25
0.89×
Q1 25
0.86×
Q4 24
5.24×
Q3 24
0.85×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

STBA
STBA

Net Interest Income$88.4M87%
Noninterest Income$13.6M13%

Related Comparisons